Prostate Cancer
📧 Sign up to get email alerts when something new happens for Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-07-24FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc. as part of a regulatory action to modify or exp…
-
EMA approval · 2026-04-22EMA Authorised: Erleada (apalutamide) — Janssen-Cilag International NV
The EMA authorised Erleada (apalutamide) for prostate cancer, under Janssen-Cilag International NV.
-
EMA approval · 2026-03-26EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.
The European Medicines Agency authorised Xtandi (enzalutamide) for prostate cancer, with Astellas Pharma Europe B.V. as the MAH (decision da…
-
EMA approval · 2026-03-26EMA Authorised: Axumin (fluciclovine (18F)) — Blue Earth Diagnostics Ireland Ltd
The European Medicines Agency authorised Axumin (fluciclovine (18F)) for radionuclide imaging in prostate cancer, marking its market access …
-
EMA approval · 2026-03-19EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
The EMA authorised Lynparza (olaparib) for multiple cancers in the European Union. Indications include ovarian cancer, breast cancer, pancre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-17EMA Authorised: Akeega (abiraterone acetate;niraparib (tosilate monohydrate)) — Janssen-Cilag International N.V.
EMA authorised Akeega, a fixed-dose combination of abiraterone acetate and niraparib (tosilate monohydrate) for castration-resistant prostat…
-
EMA approval · 2026-03-02EMA Authorised: Pylclari (Piflufolastat (18F)) — Curium Pet France
The EMA authorised Pylclari (Piflufolastat (18F)) for PET imaging to detect prostate cancer lesions; the marketing authorisation holder is C…
-
EMA approval · 2026-01-19EMA Authorised: Abiraterone Mylan (abiraterone acetate) — Mylan Pharmaceuticals Limited
The EMA authorised Abiraterone Mylan (abiraterone acetate) for prostate cancer.
-
EMA approval · 2026-01-16EMA Authorised: Abiraterone Krka (abiraterone acetate) — Krka, d.d., Novo mesto
EMA authorised Abiraterone Krka (abiraterone acetate) for prostatic neoplasms (prostate cancer); decision date 18 December 2025.
-
EMA approval · 2026-01-14EMA Authorised: Abiraterone Accord (abiraterone acetate) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Abiraterone Accord (abiraterone acetate) for use in prostate cancer, with Accord Healthcare S.L.U. …
-
EMA approval · 2025-09-30EMA Authorised: Orgovyx (relugolix) — Accord Healthcare S.L.U.
The European Medicines Agency has authorised Orgovyx (relugolix) for the treatment of prostate cancer (prostatic neoplasms) in the European …
-
EMA approval · 2025-09-30EMA Authorised: Jevtana (cabazitaxel) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Jevtana (cabazitaxel) for prostate cancer, with Sanofi Winthrop Industrie as the marketing authoriz…
-
FDA approval · 2025-09-23FDA Approved: TRELSTAR — Supplemental Application (Verity Pharmaceuticals Inc.)
FDA approved a supplemental application for TRELSTAR (triptorelin pamoate) from Verity Pharmaceuticals Inc., authorizing an updated indicati…
-
FDA approval · 2025-09-23FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for leuprolide acetate (generic) submitted by Eugia US LLC under an ANDA.
-
FDA approval · 2025-09-23FDA Approved: TRIPTODUR — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TRIPTODUR (triptorelin) from Azurity Pharmaceuticals, Inc.
-
FDA approval · 2025-09-23FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Leuprolide acetate from Amneal Pharmaceuticals LLC, granting approval for a generic version of t…
-
FDA approval · 2025-09-19FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals Inc)
FDA approved a supplemental application for Leuprolide acetate from Meitheal Pharmaceuticals Inc.
-
EMA approval · 2025-08-29EMA Authorised: Nubeqa (darolutamide) — Bayer AG
The EMA authorised Nubeqa (darolutamide) for use in castration-resistant prostate cancer, expanding the drug's EU indication for Bayer AG as…
-
EMA approval · 2025-08-04EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH
The EMA authorised Docetaxel Kabi (docetaxel) from Fresenius Kabi Deutschland GmbH for multiple cancer indications, including head and neck …
-
EMA approval · 2025-07-28EMA Authorised: Xofigo (radium (223Ra) dichloride) — Bayer AG
The EMA authorised Xofigo (radium-223 dichloride) for prostate cancer with Bayer AG as the marketing authorisation holder; decision date 28 …
-
FDA approval · 2025-05-19FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for abiraterone acetate from Mylan Pharmaceuticals, authorizing a generic version to be marketed. Ab…
-
FDA approval · 2025-05-13FDA Approved: DOCETAXEL — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approves a generic docetaxel product under an original ANDA for Meitheal Pharmaceuticals Inc.
-
EMA approval · 2025-04-03EMA Authorised: Camcevi (leuprorelin mesilate) — Accord Healthcare S.L.U.
The EMA authorised Camcevi containing leuprorelin mesilate for prostatic neoplasms (prostate cancer) in the EU, with Accord Healthcare S.L.U…
-
FDA approval · 2025-03-21FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, resulting in updated labeling and/or …
-
FDA approval · 2025-03-21FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) from Astellas Pharma US, Inc. The action updates the product's approved us…